2、地址：浙江省金华市东阳横店工业区江南路 519 号 3、检查范围：AP20014 原料药的批准前检查和日常 GMP 监督检查 证券代码：000739 证券简称：普洛药业 公告编号：2023-44 普洛药业股份有限公司 关于全资子公司浙江普洛得邦制药有限公司 通过美国 FDA 现场检查的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）的全资子公司浙江普洛得邦制 药有限公司（以下简称"得邦制药"）于 2023 年 05 月 29 日至 2023 年 06 月 02 日接受了美国食品药品监督管理局（以下简称"美国 FDA"）的 cGMP（即现行药 品生产质量管理规范）现场检查。近日，公司收到了美国 FDA 签发的现场检查报 告（EIR），此次检查以 NAI（No Action Indicated 无需采取整改）零缺陷通 过。现将相关信息公告如下： 一、FDA 现场检查的相关信息 1、公司名称：浙江普洛得邦制药有限公司 特此公告。 普洛药业股份有限公司董事会 二、通过 FDA 现场检查的品种 通过本次FDA现场检查的为 ...

证券代码：000739 证券简称：普洛药业 公告编号：2023-43 普洛药业股份有限公司 关于对下属公司担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 2023 年 8 月 29 日，普洛药业股份有限公司（以下简称"公司"）与中国建 设银行股份有限公司东阳支行（以下简称"建设银行"）签订《保证合同》（合 同编号：HTC330676300YBDB2023N01E），约定公司在对应《人民币流动资金借款 合同》（HTZ330676300LDZJ2023N02P）借款期限的 13 个月内，为公司全资子公 司浙江普洛得邦制药有限公司（以下简称"得邦制药"）提供人民币 8,000 万元 的连带责任保证。 二、担保事项履行的审议程序 公司分别于 2023 年 3 月 8 日、2023 年 4 月 18 日召开了第八届董事会第十 七次会议及 2022 年年度股东大会，会议审议通过了《关于对下属公司提供担保 的议案》，为下属 9 家子公司及孙公司在银行等金融机构的融资提供不超过人民 币 61.5 亿元的融资担保。本次对外担保额度授权期限为公司 ...

证券代码：000739 证券简称：普洛药业 公告编号：2023-42 普洛药业股份有限公司 关于产业基金备案完成的公告 关于下属全资子公司股权转让及增资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、基金备案情况 2022 年 8 月 16 日，普洛药业股份有限公司（以下简称"公司"）收到基金 管理人横店资本管理有限公司（以下简称"横店资本"）的通知，公司与关联方 横店资本共同投资设立的东阳市普洛股权投资基金合伙企业（有限合伙），已根 据《证券投资基金法》和《私募投资基金监督管理暂行办法》等法律法规的要求 在中国证券投资基金业协会完成备案手续，并取得《私募投资基金备案证明》， 具体信息如下： （1）基金名称：东阳市普洛股权投资基金合伙企业（有限合伙） （2）管理人名称：横店资本管理有限公司 （3）备案编码：SB7607 （4）备案日期：2023 年 8 月 15 日 二、风险提示 本基金可能会存在因宏观经济、行业周期、投资标的公司经营管理的变化等 因素影响，导致基金项目无法退出及基金不能实现预期收益的风险等。本基金具 有投资周期长、流动性低等特点， ...

Corporate Governance - The company reported a 61.94% participation rate in the 2022 annual shareholders' meeting held on April 18, 2023[5]. - The chairman holds 4,000,000 shares, representing 0.34% of the total share capital, while the general manager holds 500,000 shares, representing 0.04%[9]. - The company has not engaged in any related party transactions involving asset or equity acquisitions or disposals during the reporting period[46]. - The company does not have any violations regarding external guarantees during the reporting period[44]. - There are no changes in the controlling shareholder or actual controller[86]. - The company does not have any preferred shares during the reporting period[89]. - The company has not made any adjustments or restatements to previous years' accounting data[90]. - The company does not engage in entrusted financial management during the reporting period[77]. Financial Performance - Total operating revenue for the first half of 2023 reached CNY 5,954,455,753.01, an increase of 19.4% compared to CNY 4,985,677,994.46 in the same period of 2022[120]. - Net profit attributable to shareholders of the parent company for the first half of 2023 was CNY 601,065,331.00, compared to CNY 436,984,822.35 in the same period of 2022, representing a growth of 37.5%[123]. - The company's total liabilities as of June 30, 2023, amounted to CNY 6,904,885,794.26, an increase from CNY 6,497,373,460.37 at the beginning of the year[120]. - Total equity attributable to shareholders of the parent company increased to CNY 5,762,563,679.16 from CNY 5,511,878,399.44, marking a growth of 4.5%[120]. - Basic and diluted earnings per share for the first half of 2023 were CNY 0.5140, compared to CNY 0.3711 in the first half of 2022, reflecting an increase of 38.5%[123]. - The total comprehensive income for the first half of 2023 was -63,878,516.27 CNY, compared to -18,403,518.17 CNY in the same period of 2022, indicating a significant decline[126]. - The company reported a decrease in other comprehensive income, with a net amount of CNY -3,090,949.21 for the first half of 2023 compared to CNY -527,639.18 in the same period of 2022[123]. Environmental and Safety Management - The company has established an ISO14001 environmental management system and an ISO45001 occupational health and safety management system to promote safety, environmental, and occupational health standards[3]. - The company is committed to enhancing its EHS system to meet increasing environmental protection and safety standards driven by national policies[3]. - The company is focused on green production and has increased investments in environmental protection to comply with stricter regulations[3]. - The company has implemented various environmental protection laws and standards to ensure compliance and sustainability in its operations[12]. - The company has established a comprehensive framework for managing environmental impacts, including specific industry standards for emissions[14]. - The company is dedicated to achieving the strategic goals of "carbon peak and carbon neutrality" as part of its long-term vision[3]. - The company reported a total of 128.47 mg/m³ of nitrogen oxides (NOx) emissions, which is below the regulatory limit of 250 mg/m³ for fluidized bed incinerators[17]. - The company achieved a chemical oxygen demand (COD) discharge of 354.96 mg/L, significantly lower than the limit of 500 mg/L set by local environmental regulations[17]. - The ammonia nitrogen (NH3-N) level was recorded at 12.99 mg/L, which is also below the regulatory threshold of 25 mg/L[17]. - The company has implemented a comprehensive wastewater treatment process that includes neutralization, coagulation, and biological treatment to effectively reduce COD and ammonia nitrogen levels[19]. - Solid waste is categorized and managed according to national and local regulations, with hazardous waste being treated by qualified disposal units[20]. - The company utilizes a sophisticated flue gas treatment system that includes SNCR denitrification and multiple filtration methods to ensure compliance with emission standards[20]. - The company has established a continuous monitoring system for air pollutants, ensuring that emissions remain within regulatory limits[21]. - The company is committed to expanding its environmental protection measures in line with evolving regulations and standards[21]. - The company has reported a significant reduction in sulfur dioxide (SO2) emissions, achieving levels as low as 0.00 mg/m³ in certain areas[18]. - The company is actively pursuing new technologies and processes to enhance its environmental performance and reduce pollutant discharges[21]. - The company has established an EHS management organization across all subsidiaries, conducting safety risk assessments and developing comprehensive emergency response plans, which are filed with local environmental authorities[22]. - The company has implemented self-monitoring plans for pollutants in accordance with key pollutant monitoring requirements, utilizing automatic, manual, and periodic commissioned monitoring methods[23]. - The company has maintained effective control over environmental risks, with no sudden environmental incidents reported throughout the year[40]. - The company has completed the construction of new hazardous waste storage facilities at its subsidiaries, ensuring compliance with safety and environmental standards[39]. - The company has been recognized as a "Healthy Promoting Enterprise" in Zhejiang Province, reflecting its commitment to employee health and well-being[42]. Shareholder Returns - The company has consistently distributed cash dividends to shareholders, amounting to 35% of the distributable profits achieved in recent years, ensuring shareholder returns[24]. Market and Product Development - The company is actively pursuing product transformation and upgrading to adapt to market demands and regulatory changes[2]. - The company is focusing on expanding its market presence and developing new products, although specific figures were not disclosed in the provided data[126]. - The company continues to focus on expanding its market presence and enhancing its product offerings in the pharmaceutical sector[197].

普洛药业股份有限公司独立董事 关于控股股东及其他关联方占用公司资金、 公司对外担保情况的专项说明和独立意见 根据中国证监会《关于规范上市公司与关联方资金往来及上市公司对外担保 若干问题的通知》(证监发[2017]16号)、《关于规范上市公司对外担保行为的通 知》（证监发[2005]120号）及《公司章程》等有关规定，我们作为普洛药业股 份有限公司（以下简称"公司"）的独立董事，基于独立客观的立场，本着审慎 负责的态度，对公司控股股东及其他关联方资金往来和对外担保情况进行了认真 审查，现发表如下专项说明和独立意见： 陈凌 钱娟萍 潘伟光 2023 年 8 月 14 日 独立董事（签署）： 截至2023年6月30日，公司不存在控股股东及其他关联方违规占用公司资金 的情形，也不存在任何违规对外担保行为。 普洛药业股份有限公司董事会 ...

| | | 占用方与上市公 | 上市公司核算的 | 2023年期初占用 | 2023年 度1-6月 | 2023年 度1-6月 | 2023年 度1-6月 | 2023年6月3 0日 | 占用形成原 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 司的关联关系 | 会计科目 | 资金余额 | 占用累计发生金 额（不含利息） | 占用资金的利息 （如 有） | 偿还累计发生金 额 | 占用资金余额 | 因 | 占用性质 | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小 计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小 计 | - | - | - | | | | | | | - | | 其他关联方及其附属企业 | | | | | | | | | | | | 小 计 | - | - | - | | | | | | | - | | ...

证券简称： 海昇药业 证券代码： 870656 浙江海昇药业股份有限公司 1-1-0 浙江省衢州市高新技术产业园区华阳路 36 号 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实 陈述。 浙江海昇药业股份有限公司招股说明书（申报稿） 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由发行人自行负 责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担股票依法发行后因发 行人经营与收益变化或者股票价格变动引致的投资风险。 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律效 力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 1-1-1 声明 发行人及全体董事、监事、高级管理人员承诺招股说明书及其他信息披露资料不存在虚 假记载、误导性陈述或者重大遗漏，并对其真实性、准确性、完整性承担相应的法律责任。 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资 ...

Financial Performance - The company's operating revenue for Q1 2023 reached ¥3,085,538,744.52, representing a 46.83% increase compared to ¥2,101,428,825.31 in the same period last year[17] - The total operating revenue for the first quarter of 2023 was RMB 3,085,538,744.52, an increase of 46.9% compared to RMB 2,101,428,825.31 in the same period last year[23] - Net profit attributable to shareholders for Q1 2023 was ¥239,309,926.36, up 57.35% from ¥152,091,656.06 year-over-year[32] - The net profit for the first quarter of 2023 was RMB 239,308,006.44, representing a 57.4% increase from RMB 152,091,656.06 in the same quarter of the previous year[24] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥233,618,771.10, reflecting a 71.90% increase from ¥135,904,532.94 in the previous year[32] Operating Costs and Expenses - The operating cost for Q1 2023 was ¥2,222,844,353.53, which is a 44.80% increase from ¥1,535,066,594.09 year-on-year, primarily due to the increase in operating revenue[17] - The total operating costs for the first quarter of 2023 were RMB 2,727,579,280.84, up 40.8% from RMB 1,936,664,962.32 in the previous year[24] - R&D expenses increased by 42.14% to ¥202,240,389.62 from ¥142,277,701.47 in the previous year, indicating a significant investment in new product development[17] - Research and development expenses for the first quarter of 2023 amounted to RMB 202,240,389.62, which is a 42.2% increase compared to RMB 142,277,701.47 in the previous year[24] Assets and Liabilities - The company's total assets as of the end of Q1 2023 were ¥12,683,652,944.07, up from ¥12,016,599,023.18 at the beginning of the year[9] - The total liabilities as of the end of the first quarter of 2023 were RMB 6,924,825,286.56, an increase from RMB 6,497,373,460.37 at the end of the previous year[23] - The total liabilities increased, with short-term borrowings rising to ¥673,953,477.78 from ¥562,811,090.10, reflecting increased financing needs[9] - The company's cash and cash equivalents decreased, with other current assets dropping to ¥102,317,739.61 from ¥139,621,228.25, indicating tighter liquidity[9] Cash Flow - The net cash flow from operating activities was ¥222,944,074.02, which is a 29.85% increase compared to ¥171,696,287.82 in the same period last year[32] - Operating cash inflow for the current period reached $2,181,544,246.36, a significant increase from $1,512,778,824.01 in the previous period, reflecting a growth of approximately 44.2%[50] - Cash received from sales of goods and services was $1,996,810,525.10, compared to $1,369,763,853.07, reflecting an increase of about 46.0%[50] - Cash outflow from investing activities was $199,419,106.10, compared to $221,739,313.74 in the previous period, showing a decrease of approximately 10.1%[51] - Net cash flow from financing activities decreased by 71.66% to ¥102,872,647.96 from ¥363,036,069.47 in the previous year, primarily due to increased loan repayments[37] Shareholder Equity - The total equity attributable to shareholders of the parent company was RMB 5,751,482,414.06, up from RMB 5,511,878,399.44 in the previous year[23] - Shareholders' equity attributable to the parent company was ¥5,751,482,414.06, up 4.35% from ¥5,511,878,399.44 at the end of the previous year[32] - The weighted average return on equity for Q1 2023 was 4.24%, an increase from 2.96% in the same period last year[32] Other Information - The company reported a net loss from investment of ¥7,432,195.11, a decline of 178.55% compared to a profit of ¥9,461,798.73 in the previous year[17] - The fair value change income was ¥4,192,034.14, a significant recovery from a loss of ¥4,041,823.60 in the same period last year, indicating improved market conditions[17] - The company has not disclosed any new product developments or market expansion strategies in the provided data[26] - The first quarter report was not audited, indicating that the figures are preliminary and subject to change[27]

重要内容提示： 普洛药业股份有限公司（以下简称"公司"）已于 2023 年 3 月 10 日在《证 券时报》和巨潮资讯网（www.cninfo.com.cn）披露公司 2022 年年度报告。为进 一步加强与投资者的深入交流，使投资者更加全面、深入地了解公司情况，公司 将于 2023 年 3 月 28 日（星期二）下午 15：30-17：00 通过易董价值在线平台 （www.ir-online.cn）举行 2022 年年度业绩说明会。 一、说明会类型 证券代码：000739 证券简称：普洛药业 公告编号：2023－24 普洛药业股份有限公司 关于举行 2022 年年度报告网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 （3）投资者可于 2023 年 3 月 28 日前通过小程序进行会前提问，公司将通 过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题进行回答。 本次业绩说明会以网络方式召开，公司将针对 2022 年年度业绩和经营情况 相关事宜与投资者进行互动交流，在信息披露允许的范围内就投资者普遍关注的 问题进行回答。 二、说明会 ...

首次公开发行股票并在主板上市 招股说明书 （注册稿） 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 浙江海森药业股份有限公司 Zhejiang Haisen Pharmaceutical Co., Ltd. （浙江省东阳市六石街道香潭村） 浙江海森药业股份有限公司 首次公开发行股票招股说明书（注册稿） 发行人声明 本公司的发行申请尚需经深圳证券交易所和中国证监会履行相应程序。本招股说明 书不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当以正式公告的招股 说明书作为投资决定的依据。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行人注册 申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈 利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反的声明均 属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行人自行 负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担股票依法发行 后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 浙江海森药业股份有限公司 ...